Tripodi A, Chantarangkul V, Mannucci P M
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Medical Specialties, University and IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy.
J Thromb Haemost. 2008 Feb;6(2):243-8. doi: 10.1111/j.1538-7933.2008.02827.x. Epub 2007 Nov 6.
The prothrombin time (PT) test once designed by Dr Quick to investigate patients with obstructive jaundice was later adapted and standardized by means of the international normalized ratio (INR) to monitor patients on treatment with vitamin K antagonists (VKA). After more than 70 years from its introduction it is now time to think about its standardization for those very patients for whom it was intended at the beginning of its history. Two studies carried out independently and published recently in the same issue of a specialized journal do exploit the very same idea on how to accomplish this standardization. Both of them confirm previous anecdotal observations that the INR as devised for patients on VKA (INR(vka)) is not valid to harmonize PT results for patients with chronic liver disease. This fact, that at first sight may appear academic, has important consequences because the PT INR is used to construct the model for end-stage liver disease (MELD) scores, which is widely used to prioritize patients for liver transplantation. The two studies further demonstrate that an alternative calibration model, modified from that recommended by the World Health Organization for patients on VKA, may be feasible also for patients with chronic liver disease. This alternative calibration model, which calls for the substitution of plasmas from patients on VKA with those from patients with chronic liver disease, may be highly beneficial to harmonize the calculation of the MELD score, with important implications for the prioritization of patients for liver transplantation.
凝血酶原时间(PT)测试最初由奎克博士设计用于研究阻塞性黄疸患者,后来通过国际标准化比值(INR)进行了调整和标准化,以监测接受维生素K拮抗剂(VKA)治疗的患者。在其引入70多年后,现在是时候考虑对那些在其历史开端就针对的患者进行标准化了。最近在同一期专业期刊上独立发表的两项研究确实利用了关于如何实现这种标准化的相同想法。它们都证实了先前的轶事观察结果,即针对VKA患者设计的INR(INR(vka))对于协调慢性肝病患者的PT结果无效。这一乍一看可能显得学术性的事实具有重要影响,因为PT INR用于构建终末期肝病(MELD)评分模型,该模型被广泛用于确定肝移植患者的优先顺序。这两项研究进一步表明,一种从世界卫生组织为VKA患者推荐的模型修改而来的替代校准模型,对于慢性肝病患者也可能是可行的。这种替代校准模型要求用慢性肝病患者的血浆替代VKA患者的血浆,可能对协调MELD评分的计算非常有益,对肝移植患者的优先排序具有重要意义。